Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings In Brief

This article was originally published in The Gray Sheet

Executive Summary

MediSpectra: Proceeds from a $13 mil. round of financing will be used to support a pivotal randomized, controlled clinical study enrolling 2,000 women to evaluate its Luma cervical imaging device. The Series F preferred rights financing, announced Aug. 21, was led by AIG Global Investment Corp. and raises the privately held, Lexington, Massachusetts firm's total venture capital funding to $56 mil. The Luma system combines fluorescence and white light to completely scan the cervix in 12 seconds and project it onto a monitor, MediSpectra says. "Our initial goal is to use the Luma system in combination with the colposcope, thereby improving the detection of high-grade pre-cancerous disease," CEO Robert Anacone notes...
Advertisement

Related Content

MediSpectra Begins Cervical Imaging Pivotal Study On Strength Of Pilot Data
MediSpectra Begins Cervical Imaging Pivotal Study On Strength Of Pilot Data
Advertisement
UsernamePublicRestriction

Register

MT017057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel